InterCure Ltd. (INCR) Stock Price & Analysis
InterCure Ltd. (INCR) closed at USD 4.65 on Thursday, October 15, 2026, down 1.27% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.71; the Oct 15, 2026 session ranged USD 4.65–4.94 on volume of 5,770 shares. Market capitalization is $69.77M, with a 52-week range of USD 3.4–7.95 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/INCR.md
Key facts (INCR)
- Analysts: None.
- Total return with dividends: 1Y -39.6% vs S&P 500 +18.1%; 5Y -86.9% vs S&P 500 +85.1%.
Analysts (INCR)
Consensus None.
Total return (dividends reinvested) (INCR)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -39.6% | -86.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -39.7% | -33.3% |
| Volatility (annualized) | 65.7% | 63.4% |
| Max drawdown | -54.1% (Oct 2025→Mar 2026) | -91.2% (Nov 2021→Mar 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 4.65 |
|---|---|
| Change | ▼ 1.27% (down) |
| Previous Close | USD 4.71 |
| Open | USD 4.81 |
| Day Range | USD 4.65 – 4.94 |
| 52-Week Range | USD 3.4 – 7.95 |
| Volume | 5,770 shares |
| Market Cap | $69.77M |
| Exchange | NGM |
Technical Analysis (INCR)
Nexqual's technical model rates INCR "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.54 (neutral) |
| vs SMA50 | Below (USD 5.16) |
| MACD | -0.1 (negative) |
Analyst Ratings (INCR)
Wall Street analysts rate INCR "None", per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | None |
|---|
Earnings (INCR)
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (INCR)
| Revenue Growth (latest quarter, YoY) | +23.90% |
|---|---|
| Gross Margin | +15.06% |
| Operating Margin | +0.00% |
| Profit Margin | -13.22% |
| ROE | -9.27% |
| Debt / Equity | 0.46 |
| Current Ratio | 1.48 |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (INCR)
Nexqual rates InterCure Ltd.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — Debt/Equity 0.5x |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -9%, ROA -5.8% |
Ownership (INCR)
| Insider Ownership | +38.21% |
|---|---|
| Institutional Ownership | +1.05% |
| Shares Outstanding | 15.00M |
| Float | 6.65M |
| Short % of Float | +0.04% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (INCR)
InterCure Ltd. is led by Alexander Rabinovich (age 54), Founder, CEO & Chairman, per Nexqual as of October 16, 2026 at 05:19 UTC.
| Founder, CEO & Chairman | Alexander Rabinovich (age 54) |
|---|---|
| Chief Financial Officer | Amos Cohen (age 46) |
| Chief Technology Officer | Omer Layani |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.31 | ▲ 7.13% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt